Immunohistochemical profile and clinical-pathological variables in breast cancer

Revista da Associacao Medica Brasileira

Volumn 58, Issue 2, 2012, Pages 178-187

  Cintra, Jane Rocha Duarte ^a   Teixeira, Maria Teresa Bustamante ^b   Diniz, Roberta Wolp ^b   Gonçalves Jr , Homero ^b   Florentino, Thiago Marinho ^b   de Freitas, Guilherme Fialho ^b   Oliveira, Luiz Raphael Mota ^b   dos Reis Neves, Mariana Teodoro ^b   Pereira, Talita ^c   Guerra, Maximiliano Ribeiro ^b  

^a Hospital 9 de Julho   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^c UNIVERSIDADE PRESIDENTE ANTÔNIO CARLOS   (Brazil)

Author keywords

Breast neoplasias; ErbB2 receptor; Estrogen receptors; Immunohistochemistry; Ki 67 antigen; Progesterone receptors

Indexed keywords

EID: 84861328343     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302012000200013     Document Type: Article

References (51)

1. GLOBOCAN 2008: Cancer incidence and mortality worldwide in 2008-IARC. [cited 2011 Jul 8]. Available from: http://globocan.iarc.fr/.
2. Ferlay J. Shin H. R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
5. Ministério da Saúde (Brasil). Secretaria de Atenção à Saúde. Instituto Nacional do Câncer. Coordenação de Prevenção e Vigilância. Estimativa 2010: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2010. [cited 2011 May 18] Available from: http://www.inca.gov.br/estimativa/2010/versaofinal.pdf.
6. Ministério da Saúde (Brasil). Instituto Nacional de Câncer. Câncer no Brasil: dados dos registros de base populacional. v. IV. Rio de Janeiro: INCA; 2010. [cited 2011 Jul 15]. Available from: http://www.inca.gov.br.
7. Schmidt MI, Duncan BB, Azevedo e Silva G, Menezes AM, Monteiro CA, Barreto SM, et al. Doenças crônicas não transmissíveis no Brasil: carga e desafios atuais. In: The Lancet-Saúde no Brasil. [cited 2011 Jul 20]. Available from: http://www.thelancet.com/series/health-in-brazil.
8. Guerra MR, Gallo CVM, Azevedo e Silva G. Risco de câncer no Brasil: tendências e estudos epidemiológicos mais recentes. Rev Bras Cancerol. 2005;51(3):227-34.
9. Ministério da Saúde (Brasil). Informações de Saúde. Estatísticas vitais. 2011. [cited 2011 Jul 16]. Available from: http://www.datasus.gov.br.
10. Azevedo e Silva G, Bustamante-Teixeira MT, Guerra MR, Moura L. Tendências e controle do câncer e os 20 anos do Sistema Único de Saúde no Brasil. In: Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Análise de Situação de Saúde. Saúde Brasil 2008: 20 anos do Sistema Único de Saúde (SUS) no Brasil. Brasília (DF): Ministério da Saúde; 2009. p.365-84.
11. Sorlie T. Molecular portraits of breast cancer: tumors subtypes as distinct disease entities. Eur J Cancer. 2004;40(18):2667-75.
12. Reis-Filho JS, Westbury C, Pierga JY. The impact of expression, profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59(3):225-31.
13. Viale G. Pathological work up of the primary tumor: getting the proper information out of it. Breast. 2011;20(Suppl 3): S82-6.
14. Acs G, Paragh G, Rakosy Z, Laronga C, Zhang PJ. The extent of retraction clefts correlates with lymphatic vessel density and VEGF-C expression and predicts nodal metastasis and poor prognosis in early-stage breast carcinoma. Mod Pathol. 2012;25(2):163-177.
15. Duda-Szymanska J, Sporny S. The practical value of breast cancer molecular classification. Pol Merkur Lekarski. 2011;31(181):5-8.
16. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005;18(1):26-35.
17. Amendola LCB, Vieira R. A contribuição dos genes BRCA na predisposição hereditária ao câncer de mama. Rev Bras Cancerol. 2005;51(4):325-30.
18. Hanahan D, Weinberg RA. The hall marks of cancer. Cell. 2000;100(1):57-70.
19. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907-22.
20. Salles MA, Cúrcio VS, Perez AA, Gomes DS, Gobbi H. Contribuição da imuno-histoquímica na avaliação de fatores prognósticos e preditivos do câncer de mama e no diagnóstico de lesões mamárias. J Bras Patol Med Lab. 2009; 45(3):213-22.
21. Karger S, Freiburg GH. Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Breast Care (Basel). 2010;5(3):185-7.
22. Carlos S, Vallejos HL, Gómez WR. Cruz. Clinical breast cancer. 2010;10(4):294-300.
23. Lloyd MC, Allam-Nandyala P, Purohit CN, Burke N, Coppla D, Bull MM. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it? J Pathol Inform. 2010;1:29.
24. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, Ahern R, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to estrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006;17(5):818-26.
25. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-73.
26. Piccart-Gehbart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72.
27. Guarneri V, Frassoldati A, Bruzzi P, Belfiglio M, Molino A, Bertetto O, et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer. 2008;8(5):453-56.
28. Simon R, Mirlacher M, Sauter G. Tissue microarrays in cancer diagnosis. Expert Rev Mol Diagn. 2003;3(4):421-30.
29. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127.
30. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer, 2011. Ann Oncol. 2011;22(8):1736-47.
31. Voduc KD, Cheang MCU, Tyldesley S. Breast cancer subtypes and risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684-91.
32. Dent R, Trudeau M, Pritchard KI, Hanna WN, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34.
33. Kreike B, van Kouwenhove M, Horlings H, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9(5):R65.
34. Perou CM. Molecular stratification of triple-negative breast cancers. The Oncologist. 2011;16(Suppl 1):61-70.
35. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-502.
36. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007;109(9):1721-8.
37. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemo sensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-34.
38. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcription al regulation of genes related to apoptosis and cell death. Mod Pathol. 2005;18(3):374-81.
39. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat. 2005;90(2):127-37.
40. th ed. International Union Against Cancer-UICC: Wiley-Blackwell; 2009.
41. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemestry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. Plos Med. 2010;7(5):e1000279.
42. Cassol L, Silveira Graudenz M, Zelmanowicz A, Cancela A, Werutsky G, Rovere RK, et al. Basal-like immunophenotype markers and prognosis in early breast cancer. Tumori. 2010;96(6):966-70.
43. Corrêa PB, Toralles MBP, Abe-Sandes K, Machado TMB, Bonfim TM. Câncer de mama triplo negativo e sua associação com ancestralidade africana. Rev Ci Méd Biol. 2010;9(Supl1):3-7.
44. Kaufmann M, Pusztai L. Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel. Cancer. 2011;117(8):1575-82.
45. Azevedo e Silva G, Silva AM, Caula WM. Características tumorais e sobrevida de cinco anos em pacientes com câncer de mama admitidas no Instituto Nacional de Câncer, Rio de Janeiro, Brasil. Cad Saúde Pública. 2004;20(5):1232-9.
46. Brito C, Portela MC, De Vasconcelos MTL. Assistência oncológica pelo SUS a mulheres com câncer de mama no Estado do Rio de Janeiro. Rev Saúde Pública. 2005;39(6):874-81.
47. De Moraes AB, Zanini RR, Turchiello MS. Estudo da sobrevida de pacientes com câncer de mama atendidas no hospital da Universidade Federal de Santa Maria, Rio Grande do Sul, Brasil. Cad Saúde Pública. 2006;22(10):2219-28.
48. Guerra MR, Gulnar ASM, Bustamante-Teixeira MT. Sobrevida de cinco anos e fatores prognósticos em coorte de pacientes com câncer de mama assistidas em Juiz de Fora, Minas Gerais, Brasil. Cad Saúde Pública. 2009;25(11):2455-66.
49. Field TS, Buist DSM, Doubeni C, Enger S, Fouayzi H, Hart G, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005;(35):88-95.
50. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11(3):R31.
51. Guerra MR. Sobrevida e fatores prognósticos para o câncer de mama em Juiz de Fora, Minas Gerais, na coorte diagnosticada entre 1998 e 2000 [tese]. Rio de Janeiro: Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro; 2007